• Something wrong with this record ?

The kinetic direct peptide reactivity assay (kDPRA): Intra- and inter-laboratory reproducibility in a seven-laboratory ring tria

B. Wareing, SN. Kolle, B. Birk, N. Alépée, T. Haupt, R. Kathawala, PS. Kern, L. Nardelli, H. Raabe, M. Rucki, CA. Ryan, S. Verkaart, WMA. Westerink, R. Landsiedel, A. Natsch

. 2020 ; 37 (4) : 639-651. [pub] 20200610

Language English Country Germany

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc21026764

While the skin sensitization hazard of substances can be identified using non-animal methods, the classification of potency into UN GHS sub-categories 1A and 1B remains challenging. The kinetic direct peptide reactivity assay (kDPRA) is a modification of the DPRA wherein the reaction kinetics of a test substance towards a synthetic cysteine-containing peptide are evaluated. For this purpose, several concentrations of the test substance are incubated with the synthetic peptide for several incubation times. The reaction is stopped by addition of monobromobimane, which forms a fluorescent complex with the free cysteine of the model peptide. The relative remaining non-depleted amount of peptide is determined. Kinetic rate constants are derived from the depletion vs concentration and time matrix and used to distinguish between UN GHS sub-category 1A sensitizers and test substances in sub-category 1B/not classified test substances. In this study, we present a ring trial of the kDPRA with 24 blind-coded test substances in seven laboratories. The intra- and inter-laboratory reproducibility were 96% and 88%, respectively (both for differentiating GHS Cat 1A sensitizers from GHS Cat 1B/not classified). Following an independent peer review, the kDPRA was considered to be acceptable for the identification of GHS Cat 1A skin sensitizers. Besides GHS Cat 1A identification, the kDPRA can be used as part of a defined approach(es) with a quantitative data integration procedure for skin sensitization potency assessment. For this aim, next to reproducibility of classification, the quantitative reproducibility and variability of the rate constants were quantified in this study.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026764
003      
CZ-PrNML
005      
20211026132631.0
007      
ta
008      
211013s2020 gw f 000 0|eng||
009      
AR
024    7_
$a 10.14573/altex.2004291 $2 doi
035    __
$a (PubMed)32521036
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Wareing, Britta $u BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany
245    14
$a The kinetic direct peptide reactivity assay (kDPRA): Intra- and inter-laboratory reproducibility in a seven-laboratory ring tria / $c B. Wareing, SN. Kolle, B. Birk, N. Alépée, T. Haupt, R. Kathawala, PS. Kern, L. Nardelli, H. Raabe, M. Rucki, CA. Ryan, S. Verkaart, WMA. Westerink, R. Landsiedel, A. Natsch
520    9_
$a While the skin sensitization hazard of substances can be identified using non-animal methods, the classification of potency into UN GHS sub-categories 1A and 1B remains challenging. The kinetic direct peptide reactivity assay (kDPRA) is a modification of the DPRA wherein the reaction kinetics of a test substance towards a synthetic cysteine-containing peptide are evaluated. For this purpose, several concentrations of the test substance are incubated with the synthetic peptide for several incubation times. The reaction is stopped by addition of monobromobimane, which forms a fluorescent complex with the free cysteine of the model peptide. The relative remaining non-depleted amount of peptide is determined. Kinetic rate constants are derived from the depletion vs concentration and time matrix and used to distinguish between UN GHS sub-category 1A sensitizers and test substances in sub-category 1B/not classified test substances. In this study, we present a ring trial of the kDPRA with 24 blind-coded test substances in seven laboratories. The intra- and inter-laboratory reproducibility were 96% and 88%, respectively (both for differentiating GHS Cat 1A sensitizers from GHS Cat 1B/not classified). Following an independent peer review, the kDPRA was considered to be acceptable for the identification of GHS Cat 1A skin sensitizers. Besides GHS Cat 1A identification, the kDPRA can be used as part of a defined approach(es) with a quantitative data integration procedure for skin sensitization potency assessment. For this aim, next to reproducibility of classification, the quantitative reproducibility and variability of the rate constants were quantified in this study.
650    _2
$a alternativy testů na zvířatech $x metody $7 D000826
650    _2
$a zvířata $7 D000818
650    _2
$a biotest $x metody $7 D001681
650    _2
$a lidé $7 D006801
650    _2
$a kinetika $7 D007700
650    _2
$a laboratoře $x normy $7 D007753
650    _2
$a reprodukovatelnost výsledků $7 D015203
650    _2
$a kožní nemoci $x chemicky indukované $7 D012871
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kolle, Susanne N $u BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany
700    1_
$a Birk, Barbara $u BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany
700    1_
$a Alépée, Nathalie $u L'Oréal Research & Innovation, Aulnay-sous-Bois, France
700    1_
$a Haupt, Tina $u Givaudan Schweiz AG, Kemptthal, Switzerland
700    1_
$a Kathawala, Rishil $u Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA
700    1_
$a Kern, Petra S $u Procter & Gamble Services NV/SA, Brussels, Belgium
700    1_
$a Nardelli, Laurent $u L'Oréal Research & Innovation, Aulnay-sous-Bois, France
700    1_
$a Raabe, Hans $u Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA
700    1_
$a Rucki, Marián $u National Institute of Public Health, Centre of Toxicology and Health Safety, Prague, Czech Republic
700    1_
$a Ryan, Cindy A $u Procter & Gamble, Mason, OH, USA
700    1_
$a Verkaart, Sjoerd $u Charles River Laboratories, Den Bosch BV, The Netherlands
700    1_
$a Westerink, Walter M A $u Charles River Laboratories, Den Bosch BV, The Netherlands
700    1_
$a Landsiedel, Robert $u BASF SE Experimental Toxicology and Ecology, Ludwigshafen, Germany
700    1_
$a Natsch, Andreas $u Givaudan Schweiz AG, Kemptthal, Switzerland
773    0_
$w MED00200128 $t ALTEX $x 1868-596X $g Roč. 37, č. 4 (2020), s. 639-651
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32521036 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026132637 $b ABA008
999    __
$a ok $b bmc $g 1715495 $s 1147271
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 37 $c 4 $d 639-651 $e 20200610 $i 1868-596X $m ALTEX $n ALTEX $x MED00200128
LZP    __
$a Pubmed-20211013

Find record

Citation metrics

Archiving options